Ascendis Pharma A/S vs Teradyne, Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Teradyne, Inc. trades at $388.77 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 3.6× Ascendis Pharma A/S's market cap, and Teradyne, Inc. pays a 0.14% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TER | |
|---|---|---|
Market Cap | $16.67B | $59.34B |
Sector | Health | Technology |
52-Week High | $277.18 | $483.84 |
52-Week Low | $189.74 | $109.30 |
Enterprise Value | $17.04B | $59.09B |
Dividend Yield | — | 0.14% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →